You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 253 No. 10, March 8, 1985 TABLE OF CONTENTS
  JAMA
  •  Online Features
  PRELIMINARY COMMUNICATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (27)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Herpes Zoster

The Treatment and Prevention of Neuralgia With Adenosine Monophosphate

S. Harvey Sklar, MD, MSPH; William T. Blue, PhD; Edward J. Alexander, MD; Carol A. Bodian, DrPH

JAMA. 1985;253(10):1427-1430.


Abstract

Thirty-two adults were enrolled in a randomized, placebo-controlled double-blind trial of intramuscular injections of gel-sustained adenosine monophosphate (AMP) given three times a week for up to four weeks for acute herpes zoster. Adenosine monophosphate moderately reduced the pain soon after the start of treatment, decreased desquamation time, and promoted faster healing of the skin than placebo treatment. Adenosine monophosphate treatment reduced virus shedding and cleared the virus faster than in placebo-treated subjects. At the end of the initial four-week treatment period, 88% of AMP-treated patients were pain free, as opposed to only 43% in the placebo group. After four weeks, all patients who had not recovered from pain started receiving AMP treatment without breaking the code. All these patients recovered from pain within three weeks after initiation of treatment. No recurrence of pain or lesions was experienced from three to 18 months after the end of treatment. Adenosine monophosphate, a natural cellular metabolite, showed no side effects or toxicity during and after the treatment.

(JAMA 1985;253:1427-1430)



Author Affiliations

From the Departments of Pediatrics (Dr Sklar) and Medicine (Dr Alexander), Englewood Hospital, Englewood, NJ; the Department of Zoological and Biomedical Sciences, Ohio University, Athens (Dr Blue); and the Division of Biostatistics, School of Public Health, Columbia University, New York (Dr Bodian).


Footnotes

Reprint requests to Shingles Clinic, Englewood Hospital, 350 Engle St, Englewood, NJ 07631 (Dr Sklar).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neurologic Complications of the Reactivation of Varicella-Zoster Virus
Gilden et al.
NEJM 2000;342:635-645.
FULL TEXT  

False Hope on Drug Availability
Klapp and Bean
JAMA 1985;254:1905-1905.
ABSTRACT  

Herpes Zoster: Adenosine Monophosphate for the Prevention of Post-Neuralgia
Sklar et al.
JAMA 1985;254:912-912.
ABSTRACT  

Adenosine Monophosphate for the Treatment of Varicella Zoster Infections: A Large Dose of Caution
Sherlock and Corey
JAMA 1985;253:1444-1445.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.